RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it. https://t.co/KcnZmrEeJK
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @paulwaugh: More good news for everyone to wake up to.
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
More work to do but this is also encouraging: TChAdOx1 nCoV-19 (‘the ‘Oxford Vaccine’) appears to be better tolerated in older adults than in younger adults and has similar immunogenicity across all age groups after a boost dose. https://t.co/ZpM6RUoEof
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
Richard Horton The Lancet. The phase II results of University of Oxford/AstraZeneca #vaccines are here. Extremely encouraging news. It’s hard to believe we have got to this point in <12 months. Unbelievable levels of global collaboration. https://t.co/
ממצאי שלב 2 של אוקספורד בפירוט כפי שפורסמו בלנסט 👇 בין הנבדקים היו *200* בני 70+ בקבוצת החיסון, כולל בעלי מחלות רקע (לב/ריאות) ופיתחו תגובה טובה. אלה חדשות טובות, במקביל לשלב 3 הנמשך בימים אלה, במיוחד כשמדובר בחיסון "מסורתי" יותר ביחס לmRNA https://t.co/nZ
Excellent news. This is the one the Aussie govt put it’s money into (I believe).
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it. https://t.co/KcnZmrEeJK
RT @drfatihavsar: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV00…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @BioinfoTools: Yes! Lovely to see this (phase 2) vaccine results announcement has data with the press release! Wants, wants, wants. (Sci…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
👇
Yes! Lovely to see this (phase 2) vaccine results announcement has data with the press release! Wants, wants, wants. (Science by press release is a bit of pain.) Also good to see the cautious statements to the press. Story for non-scientists at the BBC: h
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
I report of effectiveness of vaccine against SARS-CoV2 (COVID-19) in older adults (>70 yo). Although frail candidates were excluded (CFS>=4), it's noteworthy that the humoral & cellular immunity was as good as in younger folks. https://t.co/gJbsV
A analizarlo!! 🤓
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/LnNg4mkalL
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
more good news coming from #ChAdOx1 #vaccine https://t.co/bz9XDf98gv
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Our paper on immune responses to the oxford AZ vaccine in the elderly is now out. It’s good news. https://t.co/rPIL01AU2L
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @DrDerekConnolly: The results of the Oxford Jenner Institute COVID Vaccine are stunning ⭐️ ChAdOx1 nCoV-19 appears to be better tolerat…
Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a data-light share-boosting press release. Looking forward to Phase III results in a similar format.
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
At least the Oxford/AstraZeneca results from phase 2-3 (ChAdOx1 nCoV-19 vaccine-candidate) have been "delivered" in the elegant form of a publication @TheLancet and not as press-conference...So far, so good...and again great news also for the subunit vacci
Analysis of phase-2 trail results from ChAdOx1 nCoV-19 vaccine. Antibody response seen in >99% cases, with similar response in older more vulnerable groups. https://t.co/ynEUTZDUdu
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
RT @ProfKatieEwer: Our latest data from @JennerInstitute and @OxfordVacGroup in showing that the Oxford/AZ #COVID19 #vaccine is safe and im…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Excellent and promising to fight against #Covid_19 pandemic
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Holding onto hope for Phase III results in next few weeks!
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicidad (capacidad de desarrollar una respuesta inmune luego de infección) y seguridad (documentar efectos adversos) (1/3) https://t.
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Latest data on safety and immunogenicity in older adults is out today.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/rRbeeXzpCj
The Man from Del Monte he say "Yes!"
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
Yes!
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @armycritcare: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV00…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Imagine what other issues we could collectively tackle next? Cough *climate change* cough.
Positive news! It's inspirational to watch this amazing science and working together.
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
This is nothing short of herculean effort.
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…